Teladoc Health (NYSE:TDOC) Reaches New 1-Year High – Here’s What Happened

Shares of Teladoc Health, Inc. (NYSE:TDOC) reached a new 52-week high during trading on Wednesday . The company traded as high as $9.85 and last traded at $9.6850, with a volume of 1721331 shares. The stock had previously closed at $9.27.

Analysts Set New Price Targets

A number of brokerages have issued reports on TDOC. Barclays dropped their target price on shares of Teladoc Health from $8.50 to $7.00 and set an “equal weight” rating for the company in a report on Thursday, March 26th. Weiss Ratings raised Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Bank of America lifted their price objective on Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Finally, Citigroup boosted their target price on Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 5th. Five research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Teladoc Health has an average rating of “Hold” and an average price target of $7.67.

Teladoc Health Price Performance

The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.72 and a current ratio of 2.80. The stock has a market capitalization of $1.70 billion, a PE ratio of -9.73 and a beta of 2.10. The company’s fifty day simple moving average is $7.76 and its two-hundred day simple moving average is $6.43.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.01). The business had revenue of $613.85 million during the quarter, compared to analysts’ expectations of $611.04 million. Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. The firm’s revenue for the quarter was down 2.5% on a year-over-year basis. During the same period last year, the company earned ($0.53) EPS. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. As a group, sell-side analysts predict that Teladoc Health, Inc. will post -0.92 EPS for the current year.

Insider Buying and Selling

In other Teladoc Health news, insider Carlos Nueno sold 6,196 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $47,275.48. Following the completion of the transaction, the insider owned 57,671 shares of the company’s stock, valued at approximately $440,029.73. This trade represents a 9.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Charles Divita III sold 19,132 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $145,977.16. Following the completion of the transaction, the chief executive officer directly owned 389,894 shares of the company’s stock, valued at approximately $2,974,891.22. This trade represents a 4.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 39,195 shares of company stock worth $299,058 in the last quarter. Corporate insiders own 0.70% of the company’s stock.

Institutional Trading of Teladoc Health

Large investors have recently made changes to their positions in the stock. Monaco Asset Management SAM lifted its stake in shares of Teladoc Health by 159.2% during the fourth quarter. Monaco Asset Management SAM now owns 1,956,947 shares of the health services provider’s stock valued at $13,699,000 after buying an additional 1,201,947 shares during the period. Tejara Capital Ltd acquired a new stake in Teladoc Health during the fourth quarter worth approximately $1,114,000. Jupiter Asset Management Ltd. grew its stake in Teladoc Health by 293.9% in the 4th quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider’s stock worth $27,021,000 after acquiring an additional 2,880,008 shares during the period. Nano Cap New Millennium Growth Fund L P purchased a new stake in Teladoc Health in the 4th quarter worth approximately $1,225,000. Finally, Union Square Park Capital Management LLC grew its stake in Teladoc Health by 233.3% in the 4th quarter. Union Square Park Capital Management LLC now owns 1,000,000 shares of the health services provider’s stock worth $7,000,000 after acquiring an additional 700,000 shares during the period. Institutional investors and hedge funds own 76.82% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.